Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes
Copyright © 2022 Elsevier España, S.L.U. All rights reserved..
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is associated with poorer glycemic control and a higher risk of type-2 diabetes (T2D) complications, extrahepatic and cardiovascular disease (CVD). Our study aim was to evaluate the association between NAFLD, T2D complications, and the development of overall clinical events (OCE) (CV, liver-related, and mortality) in patients with T2D.
METHODS: Prospective single-center study comprising T2D subjects with no history of CVD and non-T2D matched controls. Patients were selected from the Outpatient Diabetes Clinic of Vall d'Hebron Hospital and related primary care centers.
RESULTS: 186 diabetics and 57 controls were included. Amongst T2D, 124/186 subjects had NAFLD (66.6%). T2D-NAFLD subjects showed a heavier metabolic burden and higher median liver stiffness (5.6kPa [4.5-7.3] vs 4.8 [4.2-5.8]; p=0.004) compared to non-NAFLD diabetics. During a median follow-up of 5.6 years, 33 (17.7%) T2D patients developed OCE vs 4 (7.0%) controls (p=0.049). No differences were found for OCE between NAFLD and non-NAFLD diabetics (16.9% vs 19.4%; p=0.68). CV was the most reported outcome and only one liver event occurred. NAFLD diabetics showed more often chronic kidney disease (CKD), whereas T2D complications and subclinical CVD rates were similar. A higher liver stiffness, older age, and male gender were independently associated with OCE amongst the entire T2D population and NAFLD diabetics.
CONCLUSIONS: NAFLD and liver stiffness were associated with CKD and clinical outcomes in diabetics, respectively. A hepatic evaluation is recommended to identify high-risk T2D patients that would benefit from early referral to specialized care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Gastroenterologia y hepatologia - 46(2023), 9 vom: 23. Nov., Seite 682-691 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rivera-Esteban, Jesús [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical outcomes |
|---|
| Anmerkungen: |
Date Completed 27.10.2023 Date Revised 01.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.gastrohep.2022.11.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349482896 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349482896 | ||
| 003 | DE-627 | ||
| 005 | 20231226042730.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.gastrohep.2022.11.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349482896 | ||
| 035 | |a (NLM)36435379 | ||
| 035 | |a (PII)S0210-5705(22)00273-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rivera-Esteban, Jesús |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2023 | ||
| 500 | |a Date Revised 01.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is associated with poorer glycemic control and a higher risk of type-2 diabetes (T2D) complications, extrahepatic and cardiovascular disease (CVD). Our study aim was to evaluate the association between NAFLD, T2D complications, and the development of overall clinical events (OCE) (CV, liver-related, and mortality) in patients with T2D | ||
| 520 | |a METHODS: Prospective single-center study comprising T2D subjects with no history of CVD and non-T2D matched controls. Patients were selected from the Outpatient Diabetes Clinic of Vall d'Hebron Hospital and related primary care centers | ||
| 520 | |a RESULTS: 186 diabetics and 57 controls were included. Amongst T2D, 124/186 subjects had NAFLD (66.6%). T2D-NAFLD subjects showed a heavier metabolic burden and higher median liver stiffness (5.6kPa [4.5-7.3] vs 4.8 [4.2-5.8]; p=0.004) compared to non-NAFLD diabetics. During a median follow-up of 5.6 years, 33 (17.7%) T2D patients developed OCE vs 4 (7.0%) controls (p=0.049). No differences were found for OCE between NAFLD and non-NAFLD diabetics (16.9% vs 19.4%; p=0.68). CV was the most reported outcome and only one liver event occurred. NAFLD diabetics showed more often chronic kidney disease (CKD), whereas T2D complications and subclinical CVD rates were similar. A higher liver stiffness, older age, and male gender were independently associated with OCE amongst the entire T2D population and NAFLD diabetics | ||
| 520 | |a CONCLUSIONS: NAFLD and liver stiffness were associated with CKD and clinical outcomes in diabetics, respectively. A hepatic evaluation is recommended to identify high-risk T2D patients that would benefit from early referral to specialized care | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical outcomes | |
| 650 | 4 | |a Esteatosis hepática metabólica | |
| 650 | 4 | |a Eventos clínicos | |
| 650 | 4 | |a Fibrosis hepática | |
| 650 | 4 | |a Liver fibrosis | |
| 650 | 4 | |a Non-alcoholic fatty liver disease | |
| 650 | 4 | |a Non-invasive tests | |
| 650 | 4 | |a Test no invasivos | |
| 700 | 1 | |a Pons, Mònica |e verfasserin |4 aut | |
| 700 | 1 | |a Planas, Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Manzano-Nuñez, Ramiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Simó-Servat, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Bañeras, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Soler, María José |e verfasserin |4 aut | |
| 700 | 1 | |a Seron, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Boixadera, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Augustin, Salvador |e verfasserin |4 aut | |
| 700 | 1 | |a Simó, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira-González, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Genescà, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Pericàs, Juan M |e verfasserin |4 aut | |
| 700 | 0 | |a PRECISED consortium |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastroenterologia y hepatologia |d 1993 |g 46(2023), 9 vom: 23. Nov., Seite 682-691 |w (DE-627)NLM075187280 |x 0210-5705 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2023 |g number:9 |g day:23 |g month:11 |g pages:682-691 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gastrohep.2022.11.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2023 |e 9 |b 23 |c 11 |h 682-691 | ||